Full text

Turn on search term navigation

© 2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

An increasingly accepted concept is that the progression of colorectal cancer is accompanied by epithelial–mesenchymal transition (EMT). In our study, in order to characterize the properties of EMT in 16 colorectal cancer cell lines, the cells were first orthotopically implanted into nude mice, and the tumors in vivo, as well as cells cultured in vitro, were immunostained for EMT markers. The immunostaining revealed that seven of the cells had an epithelial phenotype with a high expression of E‐cadherin, whereas other cells showed opposite patterns, such as a high expression of vimentin (CX‐1, COLO205, CloneA, HCT116, and SW48). Among the cells expressing vimentin, some expressed vimentin in the orthotopic tumors but not in the cultured cells (SW480, SW620, and COLO320). We evaluated these findings in combination with microarray analyses, and selected five genes: CHST11, SERPINI1, AGR2, FBP1, and FOXA1. Next, we downregulated the expression of SERPINI1 with siRNA in the cells, the results of which showed reverse‐EMT changes at the protein level and in the cellular morphology. Along with immunohistochemical analyses, we confirmed the effect of the intracellular and secreted SERPINI1 protein of SW620 cells, which supported the importance of SERPINI1 in EMT. The development of therapeutic strategies targeting EMT is ongoing, including methods targeting the transforming growth factor‐β signaling pathway as well as the Wnt pathway. SERPINI1 is an important regulator of EMT. Our findings help to elucidate the signaling pathways of EMT, hopefully clarifying therapeutic pathways as well.

Details

Title
SERPINI1 regulates epithelial–mesenchymal transition in an orthotopic implantation model of colorectal cancer
Author
Matsuda, Yasufumi 1 ; Miura, Koh 2 ; Yamane, Junko 3 ; Shima, Hiroshi 4 ; Fujibuchi, Wataru 3 ; Ishida, Kazuyuki 5 ; Fujishima, Fumiyoshi 6 ; Ohnuma, Shinobu 1 ; Sasaki, Hiroyuki 1 ; Nagao, Munenori 1 ; Tanaka, Naoki 1 ; Satoh, Kennichi 7 ; Naitoh, Takeshi 1 ; Unno, Michiaki 1 

 Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan 
 Department of Surgery, Miyagi Cancer Center, Natori, Japan 
 Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan 
 Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan 
 Department of Molecular Diagnostic Pathology, Iwate Medical University School of Medicine, Morioka, Japan 
 Department of Pathology, Tohoku University Hospital, Sendai, Japan 
 Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Japan 
Pages
619-628
Section
ORIGINAL ARTICLES
Publication year
2016
Publication date
May 2016
Publisher
John Wiley & Sons, Inc.
ISSN
13479032
e-ISSN
13497006
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2289599797
Copyright
© 2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.